- Page 6 and 7:
6 Interview with the Executive Boar
- Page 8 and 9:
8 KapitelT … as in TRANSACTIONSDe
- Page 10 and 11:
10 KapitelT … as in THERAPEUTIC A
- Page 12 and 13:
12 KapitelT … as in T cellsTechno
- Page 14 and 15:
14 KapitelT … as in teamworkJoini
- Page 16 and 17:
16 KapitelT … as in TRENDFinancia
- Page 18 and 19:
18 pipelinepipelinemarketed drugsin
- Page 20 and 21:
20productsVeregen®ProduCt Indicati
- Page 22 and 23:
22productsRhuDex®Product Indikatio
- Page 24 and 25:
24productsImmunotherapiesImmunother
- Page 28:
28 the shareThe ShareShare price pe
- Page 31 and 32:
Medigene AG Annual report 2013 Kapi
- Page 34 and 35:
34 GROUP MANAGEMENT’S DISCUSSION
- Page 36 and 37:
36 GROUP MANAGEMENT’S DISCUSSION
- Page 38 and 39:
38 GROUP MANAGEMENT’S DISCUSSION
- Page 40:
40 GROUP MANAGEMENT’S DISCUSSION
- Page 44 and 45:
44 GROUP MANAGEMENT’S DISCUSSION
- Page 46 and 47:
46 GROUP MANAGEMENT’S DISCUSSION
- Page 48 and 49:
48 GROUP MANAGEMENT’S DISCUSSION
- Page 51 and 52:
MEDIGENE AG ANNUAL REPORT 2013 GROU
- Page 53 and 54:
MEDIGENE AG ANNUAL REPORT 2013 GROU
- Page 55 and 56:
MEDIGENE AG ANNUAL REPORT 2013 GROU
- Page 57 and 58:
MEDIGENE AG ANNUAL REPORT 2013 GROU
- Page 59 and 60:
MEDIGENE AG ANNUAL REPORT 2013 GROU
- Page 61 and 62:
CONTENTCONSOLIDATED FINANCIAL STATE
- Page 63 and 64:
MEDIGENE AG ANNUAL REPORT 2013 CONS
- Page 65 and 66:
MEDIGENE AG ANNUAL REPORT 2013 CONS
- Page 67 and 68:
MEDIGENE AG ANNUAL REPORT 2013 CONS
- Page 70 and 71:
70 NOTES TO THE CONSOLIDATED FINANC
- Page 72 and 73:
72 NOTES TO THE CONSOLIDATED FINANC
- Page 74 and 75:
74 NOTES TO THE CONSOLIDATED FINANC
- Page 76 and 77:
76 NOTES TO THE CONSOLIDATED FINANC
- Page 78 and 79:
78 NOTES TO THE CONSOLIDATED FINANC
- Page 80 and 81:
80 NOTES TO THE CONSOLIDATED FINANC
- Page 82 and 83:
82 NOTES TO THE CONSOLIDATED FINANC
- Page 84 and 85:
84 NOTES TO THE CONSOLIDATED FINANC
- Page 86 and 87:
86 NOTES TO THE CONSOLIDATED FINANC
- Page 88 and 89:
88 NOTES TO THE CONSOLIDATED FINANC
- Page 90 and 91: 90 NOTES TO THE CONSOLIDATED FINANC
- Page 92 and 93: 92 NOTES TO THE CONSOLIDATED FINANC
- Page 94 and 95: 94 NOTES TO THE CONSOLIDATED FINANC
- Page 96 and 97: 96 NOTES TO THE CONSOLIDATED FINANC
- Page 98 and 99: 98 NOTES TO THE CONSOLIDATED FINANC
- Page 100 and 101: 100 NOTES TO THE CONSOLIDATED FINAN
- Page 102 and 103: 102 NOTES TO THE CONSOLIDATED FINAN
- Page 104 and 105: 104 NOTES TO THE CONSOLIDATED FINAN
- Page 106 and 107: 106 NOTES TO THE CONSOLIDATED FINAN
- Page 108 and 109: 108 NOTES TO THE CONSOLIDATED FINAN
- Page 110 and 111: 110 NOTES TO THE CONSOLIDATED FINAN
- Page 112 and 113: 112 NOTES TO THE CONSOLIDATED FINAN
- Page 114 and 115: 114 NOTES TO THE CONSOLIDATED FINAN
- Page 116 and 117: 116 NOTES TO THE CONSOLIDATED FINAN
- Page 118 and 119: 118 NOTES TO THE CONSOLIDATED FINAN
- Page 120 and 121: 120 NOTES TO THE CONSOLIDATED FINAN
- Page 122 and 123: 122 NOTES TO THE CONSOLIDATED FINAN
- Page 124 and 125: 124 NOTES TO THE CONSOLIDATED FINAN
- Page 126 and 127: 126 AUDIT OPINIONAUDIT OPINIONWe is
- Page 128 and 129: 128 RESPONSIBILITY STATEMENTRESPONS
- Page 130 and 131: 130 REPORT OF THE SUPERVISORY BOARD
- Page 132 and 133: 132 REPORT OF THE SUPERVISORY BOARD
- Page 134 and 135: 134 REPORT OF THE SUPERVISORY BOARD
- Page 136 and 137: 136 GLOSSARYGLOSSARYAAAVLPAdeno-ass
- Page 138 and 139: 138 GLOSSARYEEBITDAEarnings before
- Page 142 and 143: 142 GLOSSARYTecDAXIndex of the Germ
- Page 144: 144 FINANCIAL CALENDAR/ TRADEMARKS/